Product Description
Troglitazone decreases insulin resistance (improves insulin sensitivity), which results in reduced plasma glucose and insulin levels in patients with non-insulin-dependent diabetes mellitus (NIDDM). Risk factors for cardiovascular disease such as elevated proinsulin and triglyceride levels are also reduced by troglitazone (Sourced from: https://pubmed.ncbi.nlm.nih.gov/9211083/)
Mechanisms of Action: PPAR-g Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Chile | New Zealand | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Parke-Davis
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Atherosclerosis
Phase 2: Liposarcoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AG0028 | P3 |
Completed |
Atherosclerosis |
2000-04-01 |
|
| P30CA006516 | P2 |
Completed |
Liposarcoma |
2000-01-01 |